Company: VEEAW
Filing Date: 2025-07-07
Form Type: DRS
Source: 0001213900-25-061586
Chunk: 83

Company: VEEA INC.
Filing Date: 2025-07-07
Form: DRS
Chunk 83
---
ution you
may incur if you participate in this offering. To the extent shares are issued under outstanding options and warrants at exercise prices
lower than the public offering price of our common stock in this offering, you will incur further dilution.

Your ownership may be diluted if additional capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions.

We will require additional,
substantial financing in order to complete our clinical trials. We intend to seek to raise additional funds for our operations, to finance
acquisitions or to develop strategic relationships by issuing equity or convertible debt securities in addition to the securities issued
in this offering, which would reduce the percentage ownership of our existing stockholders. Our board of directors has the authority,
without action or vote of the stockholders, to issue all or any part of our authorized but unissued shares of common or preferred stock.
Our articles of incorporation authorize us to issue up to 551,000,000 shares of common stock and 1,000,000 shares of preferred stock.
Future issuances of common or preferred stock would reduce your influence over matters on which stockholders vote and would be dilutive
to earnings per share. In addition, any newly issued preferred stock could have rights, preferences and privileges senior to those of
the common stock. Those rights, preferences and privileges could include, among other things, the establishment of dividends that must
be paid prior to declaring or paying dividends or other distributions to holders of our common stock or providing for preferential liquidation
rights. These rights, preferences and privileges could negatively affect the rights of holders of our common stock, and the right to
convert such preferred stock into shares of our common stock at a rate or price that would have a dilutive effect on the outstanding
shares of our common stock.

<div align='center'>40</div>

There is no public market for the common warrants or pre-funded warrants being offered in this offering.

There is no established public
trading market for the common warrants or pre-funded warrants being offered in this offering, and we do not expect a market to develop.
In addition, we do not intend to apply to list the common warrants or pre-funded warrants on any securities exchange or nationally recognized
trading system, including The Nasdaq Stock Market. Without an active market, the liquidity of the common warrants and pre-funded warrants
will be limited.

Holders of our common warrants and pre-funded warrants will have no rights as a common stockholder until they acquire our common stock.

Until holders of